3 ms·
Commercialization isn't just maximizing shareholder value alone. It's also the creation of startups based on IP. If I have discovered an interesting pharmacolo
by alephnerd 3y ago
Commercialization isn't just maximizing shareholder value alone. It's also the creation of startups based on IP.
If I have discovered an interesting pharmacological compound, or revolutionary ML workflow, or an optimized chipset - I'm less likely to get the funding and mentorship needed to scale out that startup in Europe compared to US, Asia, and Israel.
The EU is a large consumer market, but in my experience in Deeptech and B2B driven companies, the EMEA market is almost always a rounding error compared to the American market. It tends to be larger than APJ, but that's largely due to the fact that large APJ countries will create a domestic competitor that undercuts the American startup.
By falling behind in innovation commercialization, European countries will themselves face existential economic issues. For example, look at the Central European automotive industry and Electric Vehicles. Most of Central Europe (Germany, Austria, Hungary, Slovenia, Czechia, Slovakia, Poland) is heavily dependent on German ICE vehicle manufacturers like Volkswagen and BMW, but as Chinese and American EV competitors start eating market share globally, the value prop of the CEE Automotive Industry goes down, and has a downstream impact across other suppliers and industries (eg. Infineon, SAP, etc).